Literature DB >> 33451983

Fueling the Fire: Inflammatory Forms of Cell Death and Implications for Cancer Immunotherapy.

Sheera R Rosenbaum1, Nicole A Wilski1, Andrew E Aplin2,3.   

Abstract

Unleashing the immune system with immune checkpoint inhibitors (ICI) has significantly improved overall survival for subsets of patients with stage III/IV cancer. However, many tumors are nonresponsive to ICIs, in part due to a lack of tumor-infiltrating lymphocytes (TIL). Converting these immune "cold" tumors to "hot" tumors that are thus more likely to respond to ICIs is a major obstacle for cancer treatment. Triggering inflammatory forms of cell death, such as necroptosis and pyroptosis, may alter the tumor immune microenvironment and the influx of TILs. We present an emerging view that promoting tumor-localized necroptosis and pyroptosis may ultimately enhance responses to ICI. SIGNIFICANCE: Many tumor types respond poorly to ICIs or respond but subsequently acquire resistance. Effective therapies for ICI-nonresponsive tumors are lacking and should be guided by evidence from preclinical studies. Promoting inflammatory cell death mechanisms within the tumor may alter the local immune microenvironment toward an ICI-responsive state. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33451983      PMCID: PMC7858229          DOI: 10.1158/2159-8290.CD-20-0805

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   38.272


  183 in total

1.  TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains.

Authors:  Atsuhiro Kanayama; Rashu B Seth; Lijun Sun; Chee-Kwee Ea; Mei Hong; Abdullah Shaito; Yu-Hsin Chiu; Li Deng; Zhijian J Chen
Journal:  Mol Cell       Date:  2004-08-27       Impact factor: 17.970

2.  Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner.

Authors:  Stephanie A Conos; Kaiwen W Chen; Dominic De Nardo; Hideki Hara; Lachlan Whitehead; Gabriel Núñez; Seth L Masters; James M Murphy; Kate Schroder; David L Vaux; Kate E Lawlor; Lisa M Lindqvist; James E Vince
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

Review 3.  The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics.

Authors:  Aaron N Hata; Jeffrey A Engelman; Anthony C Faber
Journal:  Cancer Discov       Date:  2015-04-20       Impact factor: 39.397

4.  ESCRT-dependent membrane repair negatively regulates pyroptosis downstream of GSDMD activation.

Authors:  Sebastian Rühl; Kateryna Shkarina; Benjamin Demarco; Rosalie Heilig; José Carlos Santos; Petr Broz
Journal:  Science       Date:  2018-11-23       Impact factor: 47.728

5.  Calreticulin exposure dictates the immunogenicity of cancer cell death.

Authors:  Michel Obeid; Antoine Tesniere; François Ghiringhelli; Gian Maria Fimia; Lionel Apetoh; Jean-Luc Perfettini; Maria Castedo; Grégoire Mignot; Theoharis Panaretakis; Noelia Casares; Didier Métivier; Nathanael Larochette; Peter van Endert; Fabiola Ciccosanti; Mauro Piacentini; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Med       Date:  2006-12-24       Impact factor: 53.440

6.  Dysfunctional HIV-specific CD8+ T cell proliferation is associated with increased caspase-8 activity and mediated by necroptosis.

Authors:  Gaurav D Gaiha; Kevin J McKim; Matthew Woods; Thomas Pertel; Janine Rohrbach; Natasha Barteneva; Christopher R Chin; Dongfang Liu; Damien Z Soghoian; Kevin Cesa; Shannon Wilton; Michael T Waring; Adam Chicoine; Travis Doering; E John Wherry; Daniel E Kaufmann; Mathias Lichterfeld; Abraham L Brass; Bruce D Walker
Journal:  Immunity       Date:  2014-12-08       Impact factor: 31.745

7.  Extrinsic and intrinsic apoptosis activate pannexin-1 to drive NLRP3 inflammasome assembly.

Authors:  Kaiwen W Chen; Benjamin Demarco; Rosalie Heilig; Kateryna Shkarina; Andreas Boettcher; Christopher J Farady; Pawel Pelczar; Petr Broz
Journal:  EMBO J       Date:  2019-03-22       Impact factor: 11.598

8.  RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation.

Authors:  Etienne Meylan; Kim Burns; Kay Hofmann; Vincent Blancheteau; Fabio Martinon; Michelle Kelliher; Jürg Tschopp
Journal:  Nat Immunol       Date:  2004-04-04       Impact factor: 25.606

9.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

Review 10.  Inflammatory microenvironment remodelling by tumour cells after radiotherapy.

Authors:  Martin McLaughlin; Emmanuel C Patin; Malin Pedersen; Anna Wilkins; Magnus T Dillon; Alan A Melcher; Kevin J Harrington
Journal:  Nat Rev Cancer       Date:  2020-03-11       Impact factor: 60.716

View more
  25 in total

1.  Pyroptosis: a novel signature to predict prognosis and immunotherapy response in gliomas.

Authors:  Guiying He; Zhimin Chen; Shenghua Zhuo; Jingzhi Tang; Weijie Hao; Kun Yang; Chunshui Yang
Journal:  Hum Cell       Date:  2022-09-21       Impact factor: 4.374

2.  A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.

Authors:  Mai Q Nguyen; Nicole A Wilski; Timothy J Purwin; Weijia Cai; Mégane Vernon; Manoela Tiago; Andrew E Aplin
Journal:  Cancer Res       Date:  2022-07-18       Impact factor: 13.312

Review 3.  Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy.

Authors:  Weitong Gao; Xueying Wang; Yang Zhou; Xueqian Wang; Yan Yu
Journal:  Signal Transduct Target Ther       Date:  2022-06-20

4.  A Comprehensive Analysis of Pyroptosis-Related lncRNAs Signature Associated With Prognosis and Tumor Immune Microenvironment of Pancreatic Adenocarcinoma.

Authors:  Kai Zhao; Xiangyu Li; Yuanxin Shi; Yun Lu; Peng Qiu; Zhengdong Deng; Wei Yao; Jianming Wang
Journal:  Front Genet       Date:  2022-07-06       Impact factor: 4.772

Review 5.  Pyroptosis, metabolism, and tumor immune microenvironment.

Authors:  Tiantian Du; Jie Gao; Peilong Li; Yunshan Wang; Qiuchen Qi; Xiaoyan Liu; Juan Li; Chuanxin Wang; Lutao Du
Journal:  Clin Transl Med       Date:  2021-08

Review 6.  Microparticles: biogenesis, characteristics and intervention therapy for cancers in preclinical and clinical research.

Authors:  Yan Hu; Yajie Sun; Chao Wan; Xiaomeng Dai; Shuhui Wu; Pui-Chi Lo; Jing Huang; Jonathan F Lovell; Honglin Jin; Kunyu Yang
Journal:  J Nanobiotechnology       Date:  2022-04-13       Impact factor: 10.435

7.  Comprehensive Pan-Cancer Analyses of Pyroptosis-Related Genes to Predict Survival and Immunotherapeutic Outcome.

Authors:  Qilin Wang; Qian Liu; Sihan Qi; Junyou Zhang; Xian Liu; Xin Li; Chunyan Li
Journal:  Cancers (Basel)       Date:  2022-01-04       Impact factor: 6.639

8.  Identification and Characterization of Alcohol-related Hepatocellular Carcinoma Prognostic Subtypes based on an Integrative N6-methyladenosine methylation Model.

Authors:  Yue Zhang; Fanhong Zeng; Min Zeng; Xu Han; Lei Cai; Jiajun Zhang; Jun Weng; Yi Gao
Journal:  Int J Biol Sci       Date:  2021-08-14       Impact factor: 6.580

9.  NR1D1 Deletion Induces Rupture-Prone Vulnerable Plaques by Regulating Macrophage Pyroptosis via the NF-κB/NLRP3 Inflammasome Pathway.

Authors:  Zhinan Wu; Fei Liao; Guqing Luo; Yuxuan Qian; Xinjie He; Wenyi Xu; Song Ding; Jun Pu
Journal:  Oxid Med Cell Longev       Date:  2021-12-16       Impact factor: 6.543

10.  Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy.

Authors:  Elodie Lauret Marie Joseph; Amos Kirilovsky; Benoît Lecoester; Carine El Sissy; Laura Boullerot; Laurie Rangan; Amélie Marguier; Florent Tochet; Magalie Dosset; Jihane Boustani; Patrice Ravel; Romain Boidot; Laurie Spehner; Nacilla Haicheur-Adjouri; Florence Marliot; Jean-René Pallandre; Francis Bonnefoy; Viorel Scripcariu; Marc Van den Eynde; Emmanuel Cornillot; Céline Mirjolet; Franck Pages; Olivier Adotevi
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.